Cost-effectiveness analysis of rotavirus vaccination in China: Projected possibility of scale-up from the current domestic option

Table 1 Parameters and plausible ranges in the model

	Baseline	Plausible range for sensitivity analysis		Sources
Parameters
Discount rate	0.03	0	0.03	[31]
Vaccine coverage	25.3 %	10 %	28.6 %	[37, 36]
Mortality rate	0.0058 %	0.000029	0.000039	[41]
Rotateq efficacy	98 %	0	0.98	[38]
Rotateq infected	0.018 %	0	0.00018	[42]
hospitalization1^a	44 %	0	0.44	[22]
Outpatient1^a	28 %	0	0.28	[22]
Home-care1^a	28 %	0	0.28	[22]
Rotarix infected	0.1 %	0	0.001	[26]
LLR infected	0.9 %	0	0.009	[41]
hospitalization3^c	0.2 %	0	0.002	[2]
Outpatient3^c	7.9 %	0	0.079	[2]
home-care3^c	91.9 %	0	0.919	[2]
Rotarix efficacy	96.1 %	0.871	1	[25, 26]
LLR efficacy	72 %	0.63	0.79	[27]
Infection rate	78.85 %	0	0.7885	[34]
home-care2^b	32 %	0	0.32	[22]
hospitalization2 ^b	33 %	0	0.33	[22]
Outpatient2^b	35 %	0	0.35	[22]
natural protact1^d	77 %	0	0.77	[23]
natural protact2^d	83 %	0	0.83	[23]
Costs
International vaccinations	200.00	5	250	[16, 17]
LLR vaccination	24			The national tariff
Hospitalizations	570.04	0	570.04	[43]
Outpatient	104.19	0	104.19	[43]
Home-care	11.52	0	11.52	[44]
Health Effects
Mortality rate	0.0058 %	0	0.000058	[24]
QALY(Hospitalization)	0.077	0.075	0.078	[30]
QALY(Outpatient)	0.081	0	0.081	[30]
QALY(Home-care)	0.082	0	0.082	[30]

^aChildren's first post-infection treatment method (Outpatient, hospitalization, and home-care) selection probabilities
^bChildren's second post-infection treatment method (Outpatient, hospitalization, and home-care) selection probabilities
^cChildren's third post-infection treatment method (Outpatient, hospitalization, and home-care) selection probabilities
^dChildren's own protective efficacy first cured after infection,and Children's own protective efficacy second cured after infection

ISSN: 1471-2334